<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161651</url>
  </required_header>
  <id_info>
    <org_study_id>0047-19-COM</org_study_id>
    <nct_id>NCT04161651</nct_id>
  </id_info>
  <brief_title>Evaluation of Long-Term Implanted Sensor in Patients on Quality of Life</brief_title>
  <official_title>Evaluation of Long-Term Implanted Sensor in Patients on Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DYN Diagnostic LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of Long-Term Implanted Sensor in Patients on Quality of life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess satisfaction and acceptance of long-term implanted single sensor use (eversense XL)
      for up to 6 months in type 1 insulin-using patients
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in quality of life evaluated questionnaires (DTSQ)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HBA1C</measure>
    <time_frame>3 / 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time In Range (70-180 mg/dl)</measure>
    <time_frame>3 / 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time in hypoglycaemia below 70 mg/dl</measure>
    <time_frame>3 / 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time in hypoglycaemia below 54 mg/dl</measure>
    <time_frame>3 / 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM time in range difference [2 weeks before digital visit and 2 weeks after digital visit]</measure>
    <time_frame>3 / 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HFS-ii (hypoglycaemia fear survey II)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Continuous Glucose Monitor Satisfaction Scale (CGM-SAT)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any adverse event related to study device</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eversense</intervention_name>
    <description>eversense CGM</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female diagnosed with type 1 diabetes mellitus

          2. Age &gt; 18

          3. Insulin treatment for at least 1 year (Either MDI of CSII)

          4. HbA1c &lt; 11%

          5. Signing informed consent and willing to apply with study procedure

        Exclusion Criteria:

          1. History of severe hypoglycaemia in the last 3 months

          2. History of DKA in the last 3 months

          3. Any condition preventing or complicating the placement, operation or removal of the
             Sensor including upper extremity deformities or skin condition

          4. Female subjects of childbearing capacity (defined as not surgically sterile or not
             menopausal for â‰¥ 1 year) who are lactating or pregnant, intending to become pregnant,
             or not practicing birth control during the course of the study

          5. Any condition that require MRI imaging or planned MRI during the trial period

          6. Known topical or local anaesthetic allergy

          7. Known allergy to glucocorticoids

          8. History of hepatitis B, hepatitis C or HIV

          9. Any Bleeding disorder or taking anticoagulant medication

         10. Participation in other clinical trial

         11. Any disorder, which in the investigator's opinion might jeopardise subject's safety or
             compliance with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eversense</keyword>
  <keyword>type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

